<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287855</url>
  </required_header>
  <id_info>
    <org_study_id>IsKPd - IFM2018-03</org_study_id>
    <nct_id>NCT04287855</nct_id>
  </id_info>
  <brief_title>Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as&#xD;
      primary end point in patients with early Relapsed or Refractory Multiple Myeloma.&#xD;
&#xD;
      Therapeutic study, phase II, prospective, multicenter, open-label. The patients will be&#xD;
      treated until progression. Each cycle of treatment lasts 28 days. Cycle 1 to 13 : treatment&#xD;
      phase After cycle 13 : maintenance phase&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of trial treatment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Fraction of patients who experience a Minimal Residual Disease (MRD) 10-5 per IMWG (International Myeloma Working Group) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of trial treatment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>List of AE frequency (AE assessed by Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of response to the trial treatment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to relapse or death, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma, Refractory</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab, Carfilzomib, Pomalidomide and Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be able to understand and voluntarily sign an informed consent form&#xD;
&#xD;
          2. Must be able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          3. Male or female, age 18 years or older&#xD;
&#xD;
          4. Life expectancy of &gt; 6 months.&#xD;
&#xD;
          5. Must have a in R1 and R2 relapse Multiple Myeloma with a measurable disease :&#xD;
&#xD;
               -  1 to maximum 2 lines of therapy prior to study entry&#xD;
&#xD;
               -  Relapse Refractory or primary refractory or relapse&#xD;
&#xD;
               -  Must have received prior treatment with a Lenalidomide-containing regimen for at&#xD;
                  least 2 consecutive cycles&#xD;
&#xD;
          6. Must have measurable disease as defined by the following: must have a clearly&#xD;
             detectable and quantifiable monoclonal M-component value in the serum and/or urine :&#xD;
&#xD;
               -  IgG/IgA (serum M-component &gt; 5g/l),&#xD;
&#xD;
               -  Light chain (serum M-component &gt;1g/l or Bence Jones &gt; 200mg/24H),&#xD;
&#xD;
               -  Serum FLC assay (including for IgD isotypes): involved FLC level &gt; 10 mg/dl&#xD;
                  provided serum.&#xD;
&#xD;
             FLC ratio is abnormal for patients not measurable on any of the 3 above criteria.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2&#xD;
&#xD;
          8. Wash out period without MM treatment must be of 28 days minimum before C1D1, except&#xD;
             for anti CD-38 (See exclusion criteria#10).&#xD;
&#xD;
          9. Adequate bone marrow function, documented within 72 hours and without transfusion 72&#xD;
             hours prior to the first intake of investigational product (C1J1) with no growth&#xD;
             factor support (one week), defined as :&#xD;
&#xD;
               -  Absolute neutrophils ≥ 1 x109/L,&#xD;
&#xD;
               -  Untransfused Platelet count ≥ 75 x109/L,&#xD;
&#xD;
               -  Hemoglobin ≥ 8.5 g/dL.&#xD;
&#xD;
         10. Adequate organ function defined as :&#xD;
&#xD;
               -  Serum total bilirubin &lt; 2x upper limit of normal (ULN),&#xD;
&#xD;
               -  Clearance creatinine ≥ 30ml/min,&#xD;
&#xD;
               -  Serum SGOT/AST or SGPT/ALT &lt; 3x upper limit of normal (ULN).&#xD;
&#xD;
         11. Patients affiliated to an appropriate social security system.&#xD;
&#xD;
         12. A man who is sexually active with a pregnant female or a FCBP* must agree to use a&#xD;
             barrier method of birth control eg, condom with spermicidal&#xD;
             foam/gel/film/cream/suppository, even if he has had a vasectomy. All men must also not&#xD;
             donate sperm, spermatozoa during the study, for 5 months following treatment&#xD;
             discontinuation.&#xD;
&#xD;
         13. A woman FCBP* must understand and agree to use 2 reliable effective methods (a very&#xD;
             effective method and an effective additional method) of contraception simultaneously&#xD;
             without interruption :&#xD;
&#xD;
               -  For at least 28 days before starting experimental treatments,&#xD;
&#xD;
               -  Throughout the entire duration of experimental treatments,&#xD;
&#xD;
               -  During dose interruptions,&#xD;
&#xD;
               -  And for at least 5 months after the last dose of experimental treatments.&#xD;
&#xD;
         14. All patients must agree to not donate blood during the treatment period, interruptions&#xD;
             of treatment and at least 5 months after the last dose of treatment.&#xD;
&#xD;
         15. All patients must understand and accept to comply with the conditions of the&#xD;
             Pomalidomide pregnancy prevention plan (Appendix of the protocol).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other uncontrolled medical condition or comorbidity that might interfere with&#xD;
             patient's participation, including simultaneous participation to another&#xD;
             interventional clinical study.&#xD;
&#xD;
          2. Known positive for HIV or active infectious hepatitis, type B or C.&#xD;
&#xD;
          3. Patients with non-secretory MM and non-measurable MM&#xD;
&#xD;
          4. Patient with terminal renal failure that require dialysis or clearance creatinine &lt; 30&#xD;
             ml/min (calculated with MDRD formula)&#xD;
&#xD;
          5. Any uncontrolled or severe cardiovascular or pulmonary disease determined by the&#xD;
             investigator including :&#xD;
&#xD;
               -  NYHA functional classification III or IV congestive heart failure&#xD;
&#xD;
               -  LVEF (Left Ventricular Ejection Fraction) &lt; 40%&#xD;
&#xD;
               -  Uncontrolled angina, hypertension or arrhythmia&#xD;
&#xD;
               -  Myocardial infarction in the past 6 months&#xD;
&#xD;
          6. Prior history of malignancies, other than multiple myeloma, unless the patients has&#xD;
             been free of the disease for ≥ 5 years. Exceptions include the following:&#xD;
&#xD;
               -  Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Carcinoma in situ of the cervix or breast&#xD;
&#xD;
               -  Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)&#xD;
&#xD;
          7. Evidence of central nervous system (CNS) involvement&#xD;
&#xD;
          8. Ongoing active infection or other clinically significant uncontrolled cardiovascular&#xD;
             events&#xD;
&#xD;
          9. Unable to comply with IMids regulation to thromboprophylaxis, or teratogenic&#xD;
             recommandations.&#xD;
&#xD;
         10. Refractory to prior to anti CD38.Patients can be exposed to anti CD38 (any), BUT the&#xD;
             wash out period for patient pre-treated with an anti CD38 antibody must be of 4,5&#xD;
             months minimum between last dose of previous anti-CD38 antibody and the first dose of&#xD;
             isatuximab.&#xD;
&#xD;
         11. Refractory to prior carfilzomib&#xD;
&#xD;
         12. Known allergy to one of the study product (pomalidomide, isatuximab, carfilzomib) or&#xD;
             dexamethasone&#xD;
&#xD;
         13. Patient with a history of severe allergic reactions to thalidomide or lenalidomide&#xD;
&#xD;
         14. Exposed to pomalidomide&#xD;
&#xD;
         15. Known intolerance to infused protein products, sucrose, histidine, and PS80&#xD;
&#xD;
         16. Contraindications to dexamethasone&#xD;
&#xD;
         17. Any ongoing non hematological adverse event or medical history grade&gt; 2 severity&#xD;
&#xD;
         18. Pregnant or breast-feeding females&#xD;
&#xD;
         19. Refusal to participate in the study&#xD;
&#xD;
         20. Persons protected by a legal regime (guardianship, trusteeship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LELEU Xavier, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

